The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients Undergoing Lumbar Decompression and Fusion
Adogwa O, Elsamadicy AA, Sergesketter A, Oyeyemi D, Galan D, Vuong VD, Khalid S, Cheng J, Bagley CA, Karikari IO. The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients Undergoing Lumbar Decompression and Fusion. World Neurosurgery 2017, 110: e266-e270. PMID: 29109065, DOI: 10.1016/j.wneu.2017.10.147.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseCKD groupPatient demographicsKidney diseaseLumbar arthrodesisPreoperative chronic kidney diseaseInferior perioperative outcomesLumbar spine decompressionPostoperative complication profileLength of surgeryPostoperative complication rateEpisode of deliriumUrinary tract infectionDeep vein thrombosisBody mass indexIntensive care unitMajor academic institutionPerioperative complicationsPerioperative outcomesPostoperative complicationsPrimary endpointAdult patientsComplication rateLumbar decompressionPostoperative outcomesProspect of rindopepimut in the treatment of glioblastoma
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opinion On Biological Therapy 2017, 17: 507-513. PMID: 28274144, PMCID: PMC5787389, DOI: 10.1080/14712598.2017.1299705.Peer-Reviewed Original ResearchConceptsKeyhole limpet hemocyaninClinical efficacyClinical trialsEpidermal growth factor receptor variant IIIPhase III clinical trialsPhase II clinical trialPrimary malignant neoplasmsTreatment of GBMSub-group analysisTumor-specific epitopesTreatment of glioblastomaTumor-specific activityPrimary endpointClinical benefitMalignant neoplasmsPeptide vaccineInhibition of apoptosisSignificant efficacyGBM therapyRindopepimutAmino acid peptideLimpet hemocyaninVariant IIIGBM cellsEGFRvIII mutation